Oral Vancomycin as an Emerging Therapy for Inflammatory Pouch Conditions Associated With Primary Sclerosing Cholangitis
Lay Summary Oral vancomycin shows promise in treating pouchitis in patients with primary sclerosing cholangitis and ulcerative colitis. In this study, vancomycin helped reduce stool frequency, urgency, and incontinence. More research is needed to confirm its long-term benefits and best treatment practices.
Authors
- Tommaso Violante (ORCID: https://orcid.org/0000-0003-4439-5254)
- Nayantara Coelho‐Prabhu (ORCID: https://orcid.org/0000-0003-0775-4385)
- Abigail Meyers (ORCID: https://orcid.org/0000-0001-8201-2440)
- Laura E. Raffals (ORCID: https://orcid.org/0000-0002-5267-2592)
- Katie A. Dunleavy (ORCID: https://orcid.org/0000-0001-9415-4577)
- David W. Larson (ORCID: https://orcid.org/0000-0001-9177-4586)
- Blake Kassmeyer
- Siri A. Urquhart (ORCID: https://orcid.org/0000-0002-2337-0480)
Institutions
- Mayo Clinic (US)
- Medical College of Wisconsin (US)
- WinnMed (US)
- Mayo Clinic in Arizona (US)
- Mayo Clinic in Florida (US)
- ORSI Academy (BE)
Publication Details
- Journal
- Inflammatory Bowel Diseases
- Published
- 2025-06-30
- DOI
- https://doi.org/10.1093/ibd/izaf117
- Primary Topic
- Liver Diseases and Immunity
- Type
- article
- Field-Weighted Citation Impact
- 0.00